Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

Table 1

Patient characteristics.

Characteristics	Number of patients	Percent (%)
Age (years), median (range)	50 (26–70)
Gender
Male/female	25/10	71.4/28.6
ECOG performance status
0/1/2	10/23/2	28.6/65.7/5.7
Primary tumour location
Upper 1/3 (cardia/fundus)	3	8.3
Mid 1/3 (body)	17	47.2
Lower 1/3 (antrum/pylorus)	9	25.0
Diffuse (entire stomach)	5	13.9
Unknown	1	5.6
Site of metastasis
Nodal, distant	29	82.9
Peritoneum	19	54.3
Liver	9	25.7
Lung	4	11.4
Pancreas	3	8.6
Bone	3	8.6
Ureter	3	8.6
Ovary	2	5.7
Pleura	2	5.7
Number of metastatic sites
3/3	19/16	54.3/45.7
Histology
Adenocarcinoma, well; differentiated	4	11.4
Adenocarcinoma, moderately; differentiated	7	20
Adenocarcinoma, poorly; differentiated	17	48.6
Signet ring cell	5	14.3
Unclassified	2	5.7
Disease status
Initially metastatic/recurrent	27/8	77.1/22.9
CEA level
Normal/elevated/unknown	15/19/1	42.9/54.3/2.8
Haemoglobin level
Normal/decreased	14/21	40.0/60.0
Surgery
Gastrectomy/no gastrectomy	11/24	31.4/68.6
First-line regimen
DS/DOS	9/26	25.7/74.3
Progressive disease after first-line chemotherapy
During or 3 months after end of treatment	23	65.7
3 months after end of treatment	12	34.3

DS: docetaxel plus S-1; DOS: docetaxel plus S-1 with oxaliplatin; ECOG: Eastern Cooperative Oncology Group; CEA: carcinoembryonic antigen.